Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

I TRUST IVES SAGOT PICK FOR RLFTF FLIGHT DIRECTOR/CREW, 1st STAGE OF A TIMELESS FLIGHT!!

Early in the Covid-19 pandemic, a research and development (R&D) consultant at Swiss pharma company Relief Therapeutics, Yves Sagot, realised that a drug developed in the early 2000s for acute respiratory distress and other lung diseases and acquired by Biogen could be effective at treating Covid-19. \\\\.

Relief then reached out to US-based NeuroRx to help them co-develop this drug for Covid-19, because the latter has a “history of taking already known molecules and moving them very quickly through the FDA”, explains NeuroRx CEO and chairman Professor Jonathan Javitt.

https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/